[ad_1]
Treatment with Ribociclib, an innovative drug that has just arrived in Latin America, helps to increase the survival of patients with metastatic bad cancer and improve the quality of life of women who suffer from it.
"About 60 or 70% of women with bad cancer will have a subtype of cancer badociated with endocrine therapy or hormone receptor-positive.This has led to the development of new therapies," he said. said Dr. Gabriela Regalado in an interview with Efe
According to figures from the World Health Organization (WHO), cancer is the leading cause of death in the world.
At 39 Globally, this disease kills more than eight million people each year and at least 90% of all cancer deaths are caused by metastases, that is, when cancer cells invade. other organs
"Currently, the treatment is designed for women who develop metastatic disease. They may be premenopausal women, or menopausal women in combination with another treatment, and this (new) drug has shown substantial improvement, "said the specialist in internal medicine and oncology at the ABC Medical Center.
Innovation more targeted therapies, less toxic and above all improve the quality of life and survival of patients, allowing them to be integrated into their daily tasks.
"These are drugs that allow patients to have an adequate quality of life; the hair does not fall, there is no nausea-vomiting, the profile of toxic effects is very low, which is different from the systemic chemotherapy we are used to, "said Regalado.
% of initial diagnoses of cancer are completely advanced or metastatic, so it is necessary to ensure a better quality of life "or a better result."
He noted that new pharmacological therapies, if combined with treatment endocrine, "improve progression-free survival of metastatic cancer."
This, he says, controls the disease to the point that it serves women who may be in metastatic stages, with disseminated disease or even in those who die, help them to have a better result.
The new therapies, according to the specialist, inhibit two proteins called kinases "that are overactivated when there ac Canc er which allows cancer cells to grow and divide rapidly. "
Thus, the drug blocks these proteins and helps the cancer cells do not continue to replicate.
For the doctor, change the conventional treatments such as chemotherapy for the less aggressive, it gives the patient the same. hope of having an adequate quality of life, "a better profile of toxicity, better control and response".
Although in the stages where this drug acts it is no longer possible to cure cancer, these new therapies help patients to not suffer typical symptoms of the disease, such as bone pain, shortness of breath, and tiredness.
"Having these therapies that can improve the outcome makes us go off to gain more time to develop new drugs that help us to eradicate cancer in its infancy and, if metastatic disease is already there, we can manage it by many hos años. "
Ribociclib was approved in Mexico last November by the Federal Commission for the Prevention of Health Risks (Cofepris). Mexico, July 12 (EFE)
[ad_2]
Source link
